Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system

Area of Science:

• Oncology
• Nanotechnology
• Drug Delivery Systems

Background:

• Combination therapy of chemotherapy and anti-angiogenesis agents is a promising cancer treatment strategy.
• Major obstacles include impaired chemotherapy delivery due to vascular shutdown and increased tumor invasiveness from hypoxia-inducible factor-1alpha (HIF1-alpha) overexpression.
• Current strategies struggle to effectively overcome these challenges in solid tumors.

Purpose of the Study:

• To engineer a novel nanocell drug delivery system to overcome barriers in combined cancer therapy.
• To achieve temporal and focal drug release within solid tumors.
• To improve the therapeutic index and reduce systemic toxicity of cancer treatments.

Main Methods:

• Development of a 'nanocell' comprising a nuclear nanoparticle within a pegylated-lipid envelope.
• The nanocell is designed for preferential tumor uptake and sequential drug release.
• An anti-angiogenesis agent is released first from the envelope, followed by a chemotherapy agent from the inner nanoparticle.

Main Results:

• The nanocell successfully overcomes the obstacles of combined chemotherapy and anti-angiogenesis therapy.
• Temporal release leads to initial vascular shutdown followed by localized chemotherapy delivery within the tumor.
• Demonstrated improved therapeutic index with reduced toxicity compared to conventional approaches.

Conclusions:

• The nanocell represents a breakthrough in overcoming solid tumor treatment barriers.
• This technology enables an 'integrative' approach to cancer therapy by allowing for the combination of multiple agents.
• Potential for broader application in targeting diverse signaling pathways and tumor compartments.